Innotere 20, Innotere 80, 20 mg/1 ml, 80 mg/4 ml Concentrate for solution for infusion
PDF Leaflet Revision Date: 22 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including breast, lung, ovarian, prostate, and head and neck cancers.
Dosage (summary)
Administered as an IV infusion; typical doses range from 60 to 100 mg/mu00b2 every 3 weeks depending on cancer type.
Special Populations
- Hepatic impairment
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation due to teratogenic effects.
Key Drug Interactions
- CYP3A4 inhibitors
- Doxorubicin
- Cisplatin
Contraindications
- Hypersensitivity to docetaxel
- Neutrophil count < 1500 cells/mmu00b3
- Severe liver impairment
Common side effects
- Neutropenia
- Alopecia
- Nausea
- Vomiting
- Stomatitis
Counselling Points
- Monitor for hypersensitivity reactions
- Use contraception during and after treatment
- Avoid alcohol due to ethanol content
Serious warnings
- Severe hypersensitivity reactions
- Fluid retention
- Increased risk of treatment-related mortality in liver impairment
Important Disclaimer
The Innotere 20, Innotere 80, 20 mg/1 ml, 80 mg/4 ml Concentrate for solution for infusion professional information leaflet below is the property of Innovata Pharmaceuticals Pty (Ltd) and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
